DelveInsight’s, “Mesothelioma Pipeline Insight 2025” report provides comprehensive insights about 45+ companies and 50+ ...

DLL3 targeting Radio-DARPin MP0712 to enter first-in-human study in 2025, pending regulatory clearanceStrategic partnership with Orano Med on ...

(PDCs) demonstrate tumor-selective delivery and potent anticancer activityPreclinical data show robust efficacy as ...

Protein crystallization at the SER-CAT beamline at Argonne’s Advanced Photon Source proved key to the discovery of a new HIV vaccine candidate.

Simultaneous expansion and activation of both major γδ T cell subsets (Vδ1+ and Vδ2+) leverages both the rapid antigen ...

Proprietary platform represents the first known approach capable of sustained gamma-delta T cell expansion, eliminating target cells with robust potencyINB-619, a next generation gamma-delta TCE targe ...

Planegg, Martinsried Saturday, March 1, 2025, 11:00 Hrs [IST] ...

Q4 2024 Earnings Call Transcript February 26, 2025 Vir Biotechnology, Inc. beats earnings expectations. Reported EPS is ...

The TCR-TCEs specifically redirect the patient's own T cells towards the cancer cells via binding of the 3S TCR to a target (cancer-testis antigen or neoantigen) that is almost exclusively present on ...

EpimAb_LogoPlanegg/Martinsried and Shanghai, February 27, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) and EpimAb Biotherapeutics, ...

Identifying splicing-related neoantigens in gliomas opens new avenues for immunotherapy, enhancing treatment strategies for ...

The leading Advanced Merkel Cell Carcinoma Companies such as Xencor, Inc., Incyte Corporation, Millennium Pharmaceuticals, ...